Phase I Data from Avid Radiopharmaceuticals' Alzheimer's and Parkinson's Disease Imaging Programs to be Presented at the 55th Annual Society of Nuclear Medicine Meeting

Business Wire, June 12, 2008

Presentations Highlight Proof of Concept Results for Avid's Novel Molecular Imaging Agents

PHILADELPHIA -- Avid Radiopharmaceuticals, Inc. announced today that new clinical imaging data highlighting the proof of concept results for the Company's lead technology will be presented at the upcoming 55th Annual Society of Nuclear Medicine (SNM) meeting in New Orleans being held the week of June 16, 2008. The presentations will cover research and development results on several F-18 radiopharmaceuticals being studied by Avid for imaging amyloid plaque, a key pathological component of Alzheimer's disease (AD), as well as the VMAT2, a marker of dopaminergic synapse density, which is affected in diseases such as Parkinson's disease (PD) and Dementia with Lewy bodies (DLB).

"We are excited and honored that our technology will be featured in more than ten different presentations in this year's SNM scientific program," said Daniel Skovronsky, M.D., Ph.D., president and CEO of Avid. "This is an important validation of the scientific and clinical relevance of our R&D efforts to advance new PET molecular imaging agents for diagnosing and evaluating new treatment methods for slowing or reversing the progression of Alzheimer's and Parkinson's diseases. These novel approaches may be instrumental in helping to identify patients who will most benefit from emerging new treatments for these diseases."

Key presentations on Avid compounds and its R&D programs include:

* Dr. Skovronsky will present: "Results of multi-center clinical trials comparing four 18F-PET amyloid-imaging agents: Preclinical to clinical correlations" (presentation no. 133)

* Dr. Michael Pontecorvo, from Avid, will present: "Use of exploratory INDs in evaluation of 18F-labeled PET amyloid plaque imaging agents" (presentation no. 367)

* Dr. Dean Wong of Johns Hopkins Medical Center will present: "In vivo imaging of amyloid deposition in Alzheimer's disease using the novel radioligand [18F] AV-45" (presentation no. 925)

* Dr. Leroy Adler of the Adler Institute for Advanced Imaging will present: "Radiation dosimetry of 18F-AV-45 measured by PET/CT in humans" (presentation no. 1211)

* Dr. J. Edmunds, from Duke University Hospital, will present: "Novel 18F radioligand for PET imaging of Alzheimer's disease" (presentation no. 12)

* Abhinay Joshi, from Avid, will present: "A semi-automated method for quantification of 18F-labeled amyloid plaque imaging agents" (presentation no. 933)

* Dr. Kirk Frey of the University of Michigan will present: "Imaging VMAT2 in Parkinson's disease with [F-18] AV-133" (presentation no. 18)

About Avid Radiopharmaceuticals Inc.

Based in Philadelphia, PA, Avid Radiopharmaceuticals Inc. is a leader in the development of products with the potential for earlier and more effective detection, diagnosis and monitoring of brain disorders. The company is a pioneer in the development of molecular imaging agents for Alzheimer's disease that could lead to earlier diagnosis and better evaluation of drugs designed to prevent or reverse amyloid plaque build-up in the brain. Avid is currently enrolling patients in clinical studies of 18F-PET agents for imaging amyloid plaques in Alzheimer's disease and for imaging the vesicular monoamine transporter (VMAT2) in diseases involving dopaminergic degeneration such as Parkinson's disease (PD) and Dementia with Lewy Bodies (DLB). More information about Avid is available at www.avidrp.com.